Curaleaf (TSX:CURA) Stock Still Looks Undervalued Based On Sales

Curaleaf Holdings has had a mixed ride for shareholders over the past few years, and that uneven track record puts the spotlight squarely on whether the current share price lines up with the cannabis operator's sales base. After a recent bounce, investors are increasingly asking how much revenue they are actually paying for when they buy into Curaleaf today.

• Over the past 5 years the stock has fallen 66.6%, which keeps the question alive of how the market wants to value Curaleaf against the sales it generates.

• The push to acquire Aurora Cannabis, alongside Curaleaf's continued expansion such as the Boone Town Provisions deal in New Jersey, can influence how quickly reported sales scale and how much extra capital might be needed to support that growth path.

• There is a second opinion on Curaleaf Holdings worth weighing. See what analysts think Curaleaf Holdings's shares could be worth .

The issue now is whether Curaleaf's current market price is adequately supported by the level of sales the business is delivering today and is expected to produce over time.

If you are weighing Curaleaf Holdings against other ideas where price is being compared with business quality, a focused screen of 5 high quality undervalued stocks can be a useful next step.

Is Curaleaf Holdings Still Cheap on Sales?

P/S works reasonably well for Curaleaf Holdings because investors are often forced to lean on revenue when earnings are still volatile across the cannabis sector. Curaleaf trades on a P/S of 1.8x, which is below the peer group on 3.1x and also below the wider pharmaceuticals industry at 1.0x. The result is a stock that is being valued at a lower revenue multiple than many cannabis peers while still carrying a premium to the broader healthcare group that includes more traditional drug makers.

The Fair Ratio model, which folds in Curaleaf's growth profile, margins, size and risk, points to a higher P/S than where the shares change hands today. On this framework, the current 1.8x screens as undervalued. Because the recent bid for Aurora and the Boone Town Provisions expansion both lean on Curaleaf's ability to grow its sales base, the gap between price and the indicated Fair Ratio will matter for anyone weighing how much they are paying per dollar of revenue. Explore the numbers behind Curaleaf Holdings's P/S valuation .

The Curaleaf Holdings Narrative: What Would Justify Today's Price?

Narratives for Curaleaf Holdings link that P/S puzzle to concrete scenarios for the business, spelling out which growth paths, profitability levels and earnings shapes would need to play out for the share price to look meaningfully higher or lower than today. Each narrative anchors its number to a clear view on where Curaleaf Holdings' revenue trajectory, cost structure and risk profile could go next, which you can track against fresh results and news on Simply Wall St's Community page.